Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivacaftor in children aged 3 to 5 years with cystic fibrosis and a CFTR gating mutation
2015-001267-39Phase 3Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ivacaftor in cystic fibrosis (CF) (3 arms), sponsored by Vertex Pharmaceuticals. Primary endpoint: Efficacy measured by lung clearance index. Started Aug 2015; status: completed.
02
Drugs
ivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2015-001267-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001267-39.